JP2024531217A5 - - Google Patents
Info
- Publication number
- JP2024531217A5 JP2024531217A5 JP2024508545A JP2024508545A JP2024531217A5 JP 2024531217 A5 JP2024531217 A5 JP 2024531217A5 JP 2024508545 A JP2024508545 A JP 2024508545A JP 2024508545 A JP2024508545 A JP 2024508545A JP 2024531217 A5 JP2024531217 A5 JP 2024531217A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232571P | 2021-08-12 | 2021-08-12 | |
| US63/232,571 | 2021-08-12 | ||
| US202263332214P | 2022-04-18 | 2022-04-18 | |
| US63/332,214 | 2022-04-18 | ||
| US202263333037P | 2022-04-20 | 2022-04-20 | |
| US63/333,037 | 2022-04-20 | ||
| PCT/US2022/074930 WO2023019263A1 (en) | 2021-08-12 | 2022-08-12 | Engineered high fidelity omni-50 nuclease variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531217A JP2024531217A (ja) | 2024-08-29 |
| JPWO2023019263A5 JPWO2023019263A5 (https=) | 2025-08-20 |
| JP2024531217A5 true JP2024531217A5 (https=) | 2025-08-20 |
Family
ID=85201002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508545A Pending JP2024531217A (ja) | 2021-08-12 | 2022-08-12 | 遺伝子改変高忠実度ｏｍｎｉ－５０ヌクレアーゼバリアント |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250283115A1 (https=) |
| EP (1) | EP4384609A4 (https=) |
| JP (1) | JP2024531217A (https=) |
| KR (1) | KR20240043792A (https=) |
| AU (1) | AU2022326575A1 (https=) |
| CA (1) | CA3228366A1 (https=) |
| IL (1) | IL310730A (https=) |
| WO (1) | WO2023019263A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
| KR20230142740A (ko) | 2021-02-08 | 2023-10-11 | 에멘도바이오 인코포레이티드 | Omni-103 crispr 뉴클레아제 |
| CN119546757A (zh) | 2022-05-25 | 2025-02-28 | 宏基因组学公司 | 肝酶表达的补充 |
| US20260021141A1 (en) * | 2022-07-15 | 2026-01-22 | Emendobio Inc. | Strategies For Knock-Ins At APLP2 Safe Harbor Sites |
| WO2025117858A1 (en) * | 2023-11-28 | 2025-06-05 | Metagenomi, Inc. | Supplementation of liver enzyme expression |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512446B1 (en) * | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2020223514A2 (en) * | 2019-04-30 | 2020-11-05 | Emendobio Inc. | Novel omni-50 crispr nuclease |
| WO2020223553A2 (en) * | 2019-04-30 | 2020-11-05 | Emendobio Inc. | Novel omni crispr nucleases |
| US12435334B2 (en) * | 2019-11-06 | 2025-10-07 | Emendobio Inc. | Differential knockout of an allele of a heterozygous ELANE gene-II |
| WO2024168159A1 (en) * | 2023-02-08 | 2024-08-15 | Emendobio Inc. | Engineered omni-50 nuclease variants |
-
2022
- 2022-08-12 IL IL310730A patent/IL310730A/en unknown
- 2022-08-12 CA CA3228366A patent/CA3228366A1/en active Pending
- 2022-08-12 AU AU2022326575A patent/AU2022326575A1/en active Pending
- 2022-08-12 US US18/682,982 patent/US20250283115A1/en active Pending
- 2022-08-12 JP JP2024508545A patent/JP2024531217A/ja active Pending
- 2022-08-12 EP EP22856846.5A patent/EP4384609A4/en active Pending
- 2022-08-12 WO PCT/US2022/074930 patent/WO2023019263A1/en not_active Ceased
- 2022-08-12 KR KR1020247007872A patent/KR20240043792A/ko active Pending